课题基金 / 基金详情

ACTG 285 STEM CELL MOBILIZATION AND HARVESTING WITH FILGRASTIM

ACTG 285 STEM CELL MOBILIZATION AND HARVESTING WITH FILGRASTIM
使用 FILGRASTIM 动员和收获 ACTG 285 干细胞
批准号：
6275382
负责人：
Robert Turner Schooley
金额：
$3.14万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6275382
关键词：
cell motility clinical research colony stimulating factor hematopoietic stem cells human subject recombinant proteins

项目摘要

项目成果

Robert Turner Schooley的其他基金

相似基金

相关文献

中文摘要
翻译
这项试点研究的主要目标是提供描述性信息 关于骨髓干细胞从外周血收获后， 非格司亭的动员以及确定干细胞的安全性 通过该技术在不同阶段的HIV-1感染受试者中收获 与HIV-1未感染者中的这些变量相比， 受试者，以及确定HIV-1感染后的程度 外周动员该方案最初将使用非格司亭 剂量为10 mg/kg/天，在干细胞治疗所用剂量范围内 HIV-1未感染者的动员。
英文摘要
The primary goal of this pilot study is to provide descriptive information regarding bone marrow stem cells harvested from the peripheral blood after mobilization by filgrastim as well as to determine the safety of stem cell harvesting by this technique in HIV-1 infected subjects at various stages of HIV-1 infection as compared to these variables in HIV-1 uninfected subjects, as well as to determine the degree of HIV-1 infection after peripheral mobilization. The protocol will initially utilize a filgrastim dose of 10 mg/kg/day which is in the range of doses used for stem cell mobilization in HIV-1 uninfected individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
Development of Sustained-Release Anti-coronavirus Nucleoside Phosphonate compounds
Orally Active Nucleoside Phosphonates for Hepatitis C Virus
海外基金